The Journal of Thoracic and Cardiovascular Surgery, Vol 106, 1040-1046, Copyright © 1993 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association
Nonthoracotomy lead system for implantable defibrillator
BP Blakeman, HJ Sullivan, A Montoya, D Calandra, D Wilber, B Olshansky, J Kall, D Kopp and R Pifarre
Loyola University Medical Center, Department of Thoracic and Cardiovascular Surgery, Maywood, Ill. 60153.
Over a 2-year period, 110 patients underwent attempted implantation of an
automatic cardioverter-defibrillator using the nonthoracotomy lead system.
Indications included sustained monomorphic ventricular (n = 62),
nonsustained with poor ventricular function (n = 7), ventricular
fibrillation (n = 21), ventricular tachycardia/fibrillation (n = 18), and
familial long QT syndrome (n = 2). There were 90 male and 20 female
patients. Mean age was 57 +/- 15 years. Sixty percent had previous coronary
bypass or valve operations, or both. Mean left ventricular ejection
fraction was 30% +/- 14%, cardiac index was 2.4 +/- 0.9 L/m2, and systolic
pulmonary artery pressure was 41 +/- 14 mm Hg. Under general anesthesia,
the nonthoracotomy lead was introduced through the left subclavian vein.
The subcutaneous patch and generator were placed posteriorly on the
serratus muscle and left upper quadrant, respectively. The length of the
procedure was 116 +/- 44 minutes and the mean number of defibrillation
shocks for a successful implant was 8 +/- 4. Eighty-five patients (77%) had
successful implantations. Failures were due to high defibrillation
threshold (n = 23) and inability to place a right ventricular lead (n = 2).
Predictors of failure included preoperative antiarrhythmic drugs and
cardiac index of 1.8 +/- 4 L/m2 or less (p = 0.004). Three patients (2.7%)
died after the operation of heart failure (n = 2) and chronic heart
transplant rejection (n = 1). Complications included lead migration or
dislodgment (n = 8), infection (n = 1), and hematoma (n = 3). In summary,
the nonthoracotomy lead system may provide an alternative in patients
undergoing cardioverter-defibrillator implantation.